- Home
- HSBC vs AMGN Comparison
HSBC vs AMGN Comparison
Compare HSBC & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSBC
- AMGN
- Stock Information
- Founded
- HSBC 1865
- AMGN 1980
- Country
- HSBC United Kingdom
- AMGN United States
- Employees
- HSBC N/A
- AMGN N/A
- Industry
- HSBC Savings Institutions
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSBC Finance
- AMGN Health Care
- Exchange
- HSBC Nasdaq
- AMGN Nasdaq
- Market Cap
- HSBC 180.3B
- AMGN 156.2B
- IPO Year
- HSBC N/A
- AMGN N/A
- Fundamental
- Price
- HSBC $56.85
- AMGN $272.06
- Analyst Decision
- HSBC Buy
- AMGN Buy
- Analyst Count
- HSBC 1
- AMGN 19
- Target Price
- HSBC N/A
- AMGN $324.37
- AVG Volume (30 Days)
- HSBC 2.1M
- AMGN 2.8M
- Earning Date
- HSBC 04-29-2025
- AMGN 05-01-2025
- Dividend Yield
- HSBC 5.79%
- AMGN 3.50%
- EPS Growth
- HSBC N/A
- AMGN 56.16
- EPS
- HSBC 1.08
- AMGN 10.94
- Revenue
- HSBC $57,994,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- HSBC $9.13
- AMGN $7.19
- Revenue Next Year
- HSBC $1.80
- AMGN $2.37
- P/E Ratio
- HSBC $52.49
- AMGN $24.86
- Revenue Growth
- HSBC 2.38
- AMGN 15.56
- 52 Week Low
- HSBC $39.42
- AMGN $253.30
- 52 Week High
- HSBC $61.88
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- HSBC 56.91
- AMGN 38.46
- Support Level
- HSBC $56.21
- AMGN $266.02
- Resistance Level
- HSBC $57.24
- AMGN $291.61
- Average True Range (ATR)
- HSBC 0.67
- AMGN 7.29
- MACD
- HSBC 0.32
- AMGN -0.36
- Stochastic Oscillator
- HSBC 78.19
- AMGN 23.23
About HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in around 60 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.